4 Triple Negative Breast Cancer Clinical Trials in New Haven, CT (2026)

Q: How do I join a clinical trial in New Haven?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you.

Recruiting Triple Negative Breast Cancer Studies in New Haven

NCT06841354Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sac...

New Haven, CTPHASE31,000 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06103864Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemot...

New Haven, CTPHASE3625 participantsAstraZeneca

View Study Details

NCT07066189Recruiting

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

The purpose of this study is to examine whether a nutrition and exercise program can improve pathologic complete response (pCR) in women with triple-negative breast cancer (TNBC) receiving chemo-immun...

New Haven, CTNA160 participantsYale University

View Study Details

NCT06963905Recruiting

Saci Nivo Rela for TNBC

This is a randomized, open-label, phase Ib study to assess safety and efficacy of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus a fixed dose combination of nivolumab and relatlima...

New Haven, CTPHASE160 participantsYale University

View Study Details

About Triple Negative Breast Cancer Clinical Trials in New Haven

Triple-negative breast cancer (TNBC) lacks estrogen receptors, progesterone receptors, and excess HER2 protein, limiting targeted treatment options. It accounts for about 10-15% of breast cancers and tends to be more aggressive. Active research focuses on immunotherapy and novel drug combinations.

There are currently 4 triple negative breast cancer clinical trials recruiting participants in New Haven, CT. These studies are seeking a combined 1,845 participants. Research is being sponsored by Merck Sharp & Dohme LLC, AstraZeneca, Yale University. Clinical trial participation is free and participants receive study-related medical care at no cost.

Triple Negative Breast Cancer Clinical Trials in New Haven — FAQ

Are there triple negative breast cancer clinical trials in New Haven?

Yes, there are 4 triple negative breast cancer clinical trials currently recruiting in New Haven, CT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Haven?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.

Are clinical trials in New Haven free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.

What triple negative breast cancer treatments are being tested?

The 4 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for triple negative breast cancer.

Data updated October 19, 2026 from ClinicalTrials.gov